| Double hit lymphoma: the MD Anderson Cancer Center clinical experience Y Oki, M Noorani, P Lin, RE Davis, SS Neelapu, L Ma, M Ahmed, ... British journal of haematology 166 (6), 891-901, 2014 | 413 | 2014 |
| Management strategies and outcomes for very elderly patients with diffuse large B‐cell lymphoma D Chihara, JR Westin, Y Oki, MA Ahmed, B Do, LE Fayad, ... Cancer 122 (20), 3145-3151, 2016 | 85 | 2016 |
| Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by … CC Pinnix, B Dabaja, MA Ahmed, HH Chuang, C Costelloe, CF Wogan, ... International Journal of Radiation Oncology* Biology* Physics 92 (1), 113-121, 2015 | 58 | 2015 |
| Pre-Treatment Maximum Standardized Uptake Value Predicts Outcome After Frontline Therapy In Patients With Advanced Stage Follicular Lymphoma SSN Paolo Strati, Mohamed Amin Ahmed, Nathan Fowler, Loretta J. Nastoupil ... Hematologica, 2019 | 32* | 2019 |
| Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era CY Cheah, D Chihara, M Ahmed, RE Davis, LJ Nastoupil, K Phansalkar, ... Annals of Oncology 27 (5), 895-901, 2016 | 29 | 2016 |
| Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, ... Journal of Clinical Oncology 34 (15_suppl), 7516-7516, 2016 | 22 | 2016 |
| High risk diffuse large B cell lymphoma: a comparison of aggressive subtypes treated with dose adjusted chemotherapy-the University of Texas MD Anderson Experience V Sathyanarayanan, Y Oki, AK Issa, MA Ahmed, M Noorani, MA Fanale, ... Blood 128 (22), 106, 2016 | 14 | 2016 |
| SUVmax on pre-treatment FDG PET scan is not predictive of outcome in follicular lymphoma after R-CHOP threapy MA Ahmed, N Fowler, L Ma, M Noorani, K Phansalkar, FB Hagemeister, ... Blood 124 (21), 1629, 2014 | 7 | 2014 |
| Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL P Strati, MA Ahmed, LJ Nastoupil, L Feng, FB Hagemeister, LE Fayad, ... Leukemia & Lymphoma 61 (6), 1380-1387, 2020 | 6 | 2020 |
| OUTCOME OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AFTER SECOND SALVAGE THERAPY: MD ANDERSON EXPERIENCE MA Ahmed, D Chihara, N Vargas, L Ma, LE Fayad, Y Oki, FB Hagemeister, ... 13-ICML 33 (Supplement S1), 244–321, 2015 | 6 | 2015 |
| Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. G Roloff, R Faramand, I Aldoss, NE Kopmar, M Schwartz, SE Dekker, ... Journal of Clinical Oncology 41 (16_suppl), 7001-7001, 2023 | 5 | 2023 |
| Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) GW Roloff, I Aldoss, NE Kopmar, C Lin, SE Dekker, VK Gupta, ... Blood 142, 1030, 2023 | 3 | 2023 |
| Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy. P Strati, MA Ahmed, NH Fowler, FB Hagemeister, L Fayad, MA Rodriguez, ... Journal of Clinical Oncology 37 (15_suppl), 7540-7540, 2019 | 2 | 2019 |
| Prognostic value of pre‐treatment PET scan in patients with follicular lymphoma receiving frontline therapy P Strati, M Ahmed, N Fowler, F Hagemeister, L Fayad, M Rodriguez, ... Hematological Oncology 37, 53-54, 2019 | 1 | 2019 |
| Literature review on prophylaxis of deep venous thrombosis and pulmonary embolism IB Abdullah, M Ahmed, DA Alhalal, SA AlOtaibi, M Alanazi, IZ Alawami, ... International Journal of Pharmaceutical Research and Allied Sciences 8 (4 …, 2019 | 1 | 2019 |
| Analyzing patient characteristics who received (DA) EPOCH-R for high risk diffuse large B-cell lymphoma: MD Anderson Cancer Center experience KA Simar, V Sathyanarayanan, AK Issa, MA Ahmed, M Noorani, ... Blood 128 (22), 4208, 2016 | 1 | 2016 |
| R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis K Phansalkar, MA Ahmed, N Fowler, L Ma, M Noorani, ST Lee, L Feng, ... Blood, The Journal of the American Society of Hematology 124 (21), 3048-3048, 2014 | 1 | 2014 |
| Treatment outcomes and prognostic factors for primary mediastinal B-cell lymphoma: The MD Anderson experience. REDJRW Mohamed Amin Ahmed, Ramona Barac, L Jeffrey Medeiros, Long Ma, Luis ... Journal of Clinical Oncology 32 (15_suppl), 8564, 2014 | 1 | 2014 |
| The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia TE O'Connor, C Lin, G Roloff, A Zhang, I Aldoss, RG Faramand, ... Transplantation and Cellular Therapy 30 (2), S326, 2024 | | 2024 |
| Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World … C Lin, SB Tsai, G Roloff, A Zhang, I Aldoss, NE Kopmar, SE Dekker, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
Yago NietoProfessor of Medicine, The University of Texas MD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
